Clinical trials
Stem Cell Transplant clinical trials
Below are recruiting stem cell transplant clinical trials, each written for real people, not researchers. We’re tracking 596 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06799195RecruitingPhase 2
Better GVHD prevention after stem cell transplant
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Omaha, NebraskaAges 60 years+ - NCT06781333RecruitingPhase 2
Stem cells for behavior problems in Alzheimer's
This trial tests whether a single infusion of human mesenchymal stem cells (hMSC) can improve difficult behaviors like agitation, anxiety, or hallucinations in people with Alzheimer's disease. It's designed for those who have been taking antipsychotic medication for at least 4 weeks and have a study partner to help track behavior changes.
Miami, FloridaAges 55–90 - NCT06569095Recruiting
Study of stem cells in myelodysplastic syndrome
This study looks at special stem cells in the blood or bone marrow of people with myelodysplastic syndromes (MDS). It aims to better predict how the disease might progress and help guide treatment decisions.
BeijingAges 15–70 - NCT06541067RecruitingPhase 2
Posaconazole to prevent fungal infections after stem cell transplant
This trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in people who are at high risk after a stem cell transplant. If you qualify, you would take posaconazole during your recovery.
Nantes, FranceAges 18 years+ - NCT06514508RecruitingPhase 3
Stem cell collection with motixafortide and G-CSF for multiple myeloma
This trial tests a new drug, motixafortide, combined with a standard growth factor (G-CSF) to help collect stem cells for a transplant in people with multiple myeloma. It may be a good option if your myeloma is in remission and you have not had a stem cell transplant before.
Beijing, Beijing MunicipalityAges 18–78 - NCT06498973RecruitingPhase 1
Maintenance therapy after stem cell transplant for CD123-positive AML/MDS
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
Duarte, CaliforniaAges 18–75 - NCT03055247RecruitingPhase 2
Try ibuprofen plus growth factor and stem-cell mobilizer for X-CGD
This trial tests a combination of medicines to help your body release (“mobilize”) stem cells for future treatment in people with X-linked chronic granulomatous disease (X-CGD). If it works well and is safe for you, it may make stem-cell collection easier and more successful.
Rome, LazioAges 18–45 - NCT02143830RecruitingPhase 2
Stem cell transplant chemotherapy for Fanconi anemia
This Phase 2 study tests a stem cell transplant approach using adjusted chemotherapy doses for people with Fanconi anemia. It may help replace damaged bone marrow and treat blood problems like severe aplastic anemia, MDS, or leukemia.
New York, New YorkAges 3 months+ - NCT05947136Recruiting
PASCA program study after stem cell transplant for myeloma
This study checks whether the PASCA health program helps reduce complications in people with multiple myeloma after their first stem cell transplant. It may help by improving how patients manage side effects during recovery and ongoing treatment.
ÉpagnyAges 18–70 - NCT05647213RecruitingPhase 1
Skin biopsy study of stem-cell therapy for congenital heart disease
This early study takes a small skin sample to make a personalized type of heart stem cells in the future. It is testing whether this approach is safe and feasible for people with complex single-chamber congenital heart disease and advanced heart failure.
Rochester, MinnesotaAges 18–40 - NCT05509933RecruitingPhase 3
Budesonide to prevent engraftment syndrome after stem cell transplant
This Phase 3 study tests whether budesonide can prevent “engraftment syndrome” after people receive a hematopoietic (blood-forming) stem cell transplant. If it works, it may reduce complications around the time the new cells start growing and making blood cells.
Detroit, MichiganAges 18–80 - NCT05052957RecruitingPhase 2
Stem cell rescue for glioblastoma
This trial tests whether using your own blood stem cells to support high-dose chemotherapy can help treat newly diagnosed glioblastoma, an aggressive brain cancer. It aims to improve outcomes for patients whose tumors have a specific genetic marker (unmethylated MGMT) and who have had surgery.
Cleveland, OhioAges 18 years+ - NCT04708054RecruitingPhase 2/Phase 3
Venetoclax with busulfan chemo for high-risk AML or MDS
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
Houston, TexasAges 18–70 - NCT04742634RecruitingPhase 1/Phase 2
Preemptive drug DEC-C after transplant to reduce hidden cancer
This trial tests whether giving DEC-C (a decitabine-based treatment) soon after an allogeneic transplant can improve outcomes for MDS patients who still have “measurable residual disease” (hidden leftover disease) detectable by a genetic test. It also compares this approach to standard observation if the hidden disease is not detected or if the higher-risk safety checks are not met.
St Louis, MissouriAges 18–75 - NCT04392206RecruitingPhase 1
Study paste to prevent narrowing in new arm dialysis fistulas
This Phase 1 study tests a treatment (called AMSCs) to help stop scar-like narrowing at the connection point of a new arm dialysis fistula. If it works and is safe, it could improve long-term fistula function so dialysis can work better.
Jacksonville, FloridaAges 18–85 - NCT02577731Recruiting
Study of bone marrow changes after major injury or elective hip surgery
This trial studies how bone marrow and blood-making cells may behave after severe trauma or after elective (planned) hip surgery. It may help researchers understand why recovery can be harder in some people and guide better care.
Gainesville, FloridaAges 18 years+ - NCT03403699Recruiting
Stem cell treatment for damaged eye blood vessels in diabetes
This study tests human iPSC–derived (lab-grown) cells aimed at repairing fragile, damaged blood vessels in diabetic retinopathy. It also involves eye exams and a small skin biopsy to support the research.
Birmingham, AlabamaAges 21–98 - NCT03618550RecruitingPhase 2
Pembrolizumab plus chemotherapy for relapsed Hodgkin lymphoma
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
Duarte, CaliforniaAges 18 years+ - NCT07822087RecruitingPhase 1
Cell therapy for active crohn's disease
This trial tests an experimental cell therapy called ATORM-C for people with Crohn's disease who haven't gotten better with standard treatments. The goal is to see if this new treatment can help heal the intestinal ulcers that cause symptoms.
SeoulAges 19–80 - NCT07496372RecruitingPhase 3
Stem cell injection for advanced heart failure
This trial tests a treatment made from stem cells that are turned into heart muscle cells and injected directly into the heart. It is for people with advanced heart failure who are already on the best available medicines and who are scheduled to have bypass surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04871607RecruitingPhase 2
Yttrium antibody plus chemotherapy for hard-to-treat Hodgkin lymphoma
This trial studies a targeted antibody therapy with yttrium, combined with intensive chemotherapy, for adults whose Hodgkin lymphoma did not respond well or came back. It may help by delivering cancer-killing radiation directly to lymphoma cells and preparing the body for treatment after transplant conditioning.
Duarte, CaliforniaAges 18 years+ - NCT06851767Enrolling by invitationPhase 1/Phase 2
Gene therapy for X-linked severe combined immunodeficiency
This study tests a gene therapy to treat X-linked severe combined immunodeficiency (X-SCID) without a stem cell transplant from a matched sibling. It aims to improve immune function and reduce infections using your own stem cells modified to carry the correct gene.
Bethesda, MarylandAges 3–99 - NCT04293042RecruitingEarly Phase 1
BK virus treatment using donor immune cells after transplant
This early-phase study tests whether immune cells made from a donor (T cells) can treat BK virus infection in people whose immune system is weak after a stem cell transplant or chemotherapy. It may help control the virus causing bladder/urinary symptoms.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT06769191RecruitingEarly Phase 1
CD7 car-t, stem cell transplant, and kidney transplant for SIOD
This trial tests a sequence of treatments for SIOD (a genetic condition causing immune and kidney problems). First, you receive CD7 car-t cells, then a stem cell transplant from a family donor, followed by a kidney transplant from the same donor. The goal is to see if this approach is safe and can help your body accept the new kidney.
Hangzhou, ZhejiangAges Any age
Hear when a new Stem Cell Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for stem cell transplant?
- Yes. Clin2 currently lists 596 recruiting stem cell transplant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a stem cell transplant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a stem cell transplant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.